Monument Therapeutics

Monument Therapeutics is a clinical-stage biopharmaceutical company developing stratified treatments for neuropsychiatric conditions.

Its lead programme, MT1988, is being evaluated in people at clinical high risk of psychosis. A randomised, placebo-controlled Phase 1/2 study dosed its first participant in March 2026 and is assessing cognitive, clinical, biological and digital biomarkers.

Monument combines investigational medicines with cognitive assessments to study treatment response and support patient stratification in psychiatric drug development.